Lupin Limited (LUPIN) · mywealthgrid

Loading page…

About

Lupin Limited operates in pharmaceuticals within the Healthcare sector. With a market cap of ₹1,02,184 Cr and quarterly standalone revenues between ₹4,500 Cr and ₹8,300 Cr, it is a significant player in the Indian pharmaceutical market. The company demonstrates strong profitability with net profit margins ranging 17–52% across recent quarters and an ROE of 26.9%.

Face value: ₹2

Market cap

₹92,866 Cr

P/E

16.8×

P/B

4.1×

Dividend yield

1.5%

ROE

26.9%

ROCE

34.2%

Debt / equity

0.26

OPM

31.5%

EPS (TTM)

₹120.9

Book value

₹491.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Margin volatility: OPM swings from 28.9% to 52.05% across recent quarters; verify drivers—one-time items, product mix, geography concentration, or operational instability
Revenue concentration: standalone quarterly revenues range ₹4,501–₹8,277 Cr (84% variation); verify what product, segment or geography concentration drives this volatility
Pharma sector headwinds: generic pricing pressure, patent cliffs, and regulatory scrutiny (NPPA, FDA, EMA) are typical; verify Lupin's exposure and pipeline strength
Foreign-exchange and supply-chain risks; verify hedging, sourcing resilience and exposure to key procurement regions

Generated analysis · source review pending

Growth drivers

Quarterly net profits peaked at ₹2,714 Cr (Jun 2026) and ₹2,163 Cr (Mar 2026); verify whether strength from volume, pricing or margin expansion and if sustainable
D/E ratio of 0.26 is materially low; provides balance-sheet flexibility for debt-funded capex, R&D or acquisitions—verify management's capital-allocation strategy
FII holding increased from 21.71% (Mar 2026) to 22.42% (Jun 2026); verify if driven by sector tailwinds or company-specific catalysts

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹2,031.2-1%1Y

Quick read

rule-based

Pros

+Strong return on equity of 20.7% (3-yr avg)
+High return on capital employed of 25.7%
+Healthy operating margin of 31.5%
+Profit CAGR of 34.4% over the last 5 years
+Comfortable interest coverage of 18.1×

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

83/100

Business quality: 92
Growth: 84
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 50 NIFTY MIDCAP 150 NIFTY 200 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	14,256	17,494	15,560	16,369	15,375	15,163	16,405	16,642	20,011	22,708	27,958
COGS	4,778	5,339	5,274	5,846	5,431	5,362	6,481	6,780	6,643	6,842	7,326
Gross profit	9,477	12,155	10,285	10,524	9,944	9,801	9,924	9,862	13,367	15,866	20,632
	5,792	7,662	7,379	7,990	7,585	7,233	9,637	8,064	9,557	10,582	11,816
	3,685	4,493	2,907	2,533	2,359	2,568	288	1,798	3,811	5,283	8,816
OPM %	25.9%	25.7%	18.7%	15.5%	15.3%	16.9%	1.8%	10.8%	19%	23.3%	31.5%
Depreciation	487	912	1,086	1,085	970	887	1,659	881	1,197	1,169	1,376
Interest	59	153	204	308	363	141	143	274	312	295	434
	185	107	-1,070	377	-138	136	142	73	120	196	-133
Profit before tax	3,329	3,543	547	1,517	887	1,676	-1,372	716	2,422	4,015	6,873
Tax	1,059	979	288	902	1,157	449	137	269	487	709	1,517
Tax %	31.8%	27.6%	52.8%	59.4%	130.4%	26.8%	10%	37.5%	20.1%	17.7%	22.1%
	2,270	2,565	258	615	-270	1,228	-1,509	448	1,936	3,306	5,355
PAT margin %	15.9%	14.7%	1.7%	3.8%	-1.8%	8.1%	-9.2%	2.7%	9.7%	14.6%	19.2%
EPS (₹)	50.3	56.7	30.8	34.3	-6	27.1	-33.7	9.5	42.1	72	116.8
EPS adjusted (₹)	50.2	56.6	5.6	13.4	-13.5	26.8	-33.6	9.5	42	71.9	116.6
	14.9%	13.2%	16.2%	14.6%	—	24%	—	42.3%	19%	16.7%	15.4%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	90	90	90	91	91	91	91	91	91	91	91
Reserves	10,894	13,407	13,487	13,652	12,446	13,712	12,062	12,374	14,199	17,112	22,357
Minority interest	—	—	—	—	—	55	69	78	83	91	65
	7,119	—	—	—	—	4,783	3,844	4,244	2,670	5,077	5,910
	4,334	13,110	12,728	14,207	12,447	4,969	5,755	6,169	6,954	6,834	9,941
Total equity & liabilities	22,438	26,607	26,305	27,949	24,984	23,610	21,821	22,956	23,997	29,205	38,365
	3,262	8,723	7,914	8,706	7,938	7,881	7,382	8,355	8,878	9,719	10,994
CWIP	981	715	956	1,019	758	852	847	895	596	355	695
Investments	8	2,120	240	2,270	2,344	2,455	900	517	1,075	1,146	3,670
	18,187	15,050	17,195	15,954	13,944	12,423	12,692	13,189	13,449	17,984	23,006
Total assets	22,438	26,607	26,305	27,949	24,984	23,610	21,821	22,956	23,997	29,205	38,365

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.

Source XBRL ↗

Latest reported period · 31 Mar 2026 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities	Capital employed	ROCE %
Pharmaceuticals	27,812.36	7,050.27	38,128.6	15,746.22	22,382.38	31.5
Others	147.39	-177.72

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.3%	64.7%	64.6%	60.5%	59.3%	66.8%	69.9%	73.8%
EBITDA margin %	15.5%	15.3%	16.9%	1.8%	10.8%	19%	23.3%	31.5%
EBIT margin %	8.8%	9%	11.1%	-8.4%	5.5%	13.1%	18.1%	26.6%
PAT margin %	3.8%	-1.8%	8.1%	-9.2%	2.7%	9.7%	14.6%	19.2%
Working capital
Receivable days	115	129	108	95	98	86	88	86
Inventory days	240	232	279	261	242	272	292	303
Payable days	156	162	137	129	136	163	158	208
NWC days	198	199	249	227	204	195	223	181
Leverage
Current ratio	2.26	1.67	1.66	1.51	1.34	1.58	1.87	1.9
Debt to EBITDA	—	—	1.86	13.38	2.36	0.7	0.96	0.67
Debt to equity	—	—	0.35	0.32	0.34	0.19	0.3	0.26
Interest coverage	7	5.1	12.9	-8.6	3.6	8.8	14.6	18.1
Asset turnover	0.59	0.62	0.64	0.75	0.72	0.83	0.78	0.73
Return ratios
Return on assets %	2.2%	-1.1%	5.2%	-6.9%	2%	8.1%	11.3%	14%
Return on capital employed %	10%	9.9%	11.7%	-8.6%	7.3%	18.7%	24.1%	34.2%
Return on equity %	4.5%	-2.2%	8.9%	-12.4%	3.6%	13.5%	19.2%	23.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	47.06%	47.04%	47.01%	46.98%	46.96%	46.95%	46.92%	46.9%	46.9%	46.89%	46.86%	46.85%
	14.99%	16.11%	18.28%	19.32%	21.5%	22.04%	21.46%	21.25%	20.49%	21.49%	21.71%	22.42%
	29.42%	29.73%	27.76%	26.78%	25.09%	24.74%	25.41%	25.56%	26.55%	25.58%	25.32%	24.65%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0.01%	0.01%	0%	0%
	8.53%	7.12%	6.95%	6.92%	6.45%	6.27%	6.21%	6.29%	6.05%	6.03%	6.11%	6.08%
No. of shareholders	—	—	—	—	—	—	—	—	2,80,256	2,88,931	2,90,411	3,00,283

Promoter holding down 0.21 percentage points since Sep 2023.

40 deals · 16 Sept 2021 – 14 Oct 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
14 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	60,035	₹1,937.50	₹11.63 Cr
14 Oct 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	60,035	₹1,937.50	₹11.63 Cr
13 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE - ODI	Block	NSE	Sell	81,892	₹1,977.00	₹16.19 Cr
13 Oct 2025	GOLDMAN SACHS BANK EUROPE SE - ODI	Block	NSE	Buy	81,892	₹1,977.00	₹16.19 Cr
14 Jul 2025	STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUND	Block	BSE	Sell	52,861	₹1,894.70	₹10.02 Cr
14 Jul 2025	STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUND	Block	BSE	Buy	52,861	₹1,894.70	₹10.02 Cr
25 Jan 2024	SOCIETE GENERALE	Block	BSE	Buy	7,47,956	₹1,449.20	₹108.39 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	7,47,956	₹1,449.20	₹108.39 Cr
14 Nov 2022	ISHARES CORE MSCI EMERGING MARKETS ETF	Block	NSE	Buy	2,28,477	₹747.00	₹17.07 Cr
14 Nov 2022	ISHARES CORE EMERGING MARKETS MAURITIUS CO	Block	NSE	Sell	2,28,477	₹747.00	₹17.07 Cr

1–10 of 40

1 / 4

Mrs. Manju D. GuptaNon-Executive - Non Independent Director-Chairperson related to Promoter
Ms. Vinita GuptaExecutive Director-CEO
Mr. Nilesh D. GuptaExecutive Director-MD
Mr. Ramesh SwaminathanExecutive Director
Mr. Kanwar Bir Singh AnandNon-Executive - Independent Director
Mr. Mark D. McDadeNon-Executive - Independent Director
Mr. Jeffrey KindlerNon-Executive - Independent Director
Mr. Alfonso ZuluetaNon-Executive - Independent Director
Ms. Punita LalNon-Executive - Independent Director
Mr. Anand KripaluNon-Executive - Independent Director
Mr. Sunil MakhariaInterim Chief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹2,030.2 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹2,047.0	-32.7	-1.6%	₹2,047.0	18,001	+42	1,489	425
23 Nov 2026	₹2,059.0	-29.8	-1.4%	₹2,059.0	622	+21	44	425
29 Dec 2026	₹2,074.0	-8.6	-0.4%	₹2,074.0	4	+4	6	425

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

38

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
0	0	0	₹0.0	1,680

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

106

across 19 fund houses

Held by these funds

4.81%

of the company's equity

All mutual funds

14.84%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

106 schemes · 19 fund houses

		Shares
PHARMA FUND	Nippon India Mutual Fund	27.84 L	609.25	6.43%	0.609%	-0
Growth Mid Cap FundNEW	Nippon India Mutual Fund	22 L	481.45	0.92%	0.481%	—
LARGE CAP FUND	Nippon India Mutual Fund	21.78 L	476.72	0.88%	0.476%	-0
Midcap Fund	SBI Mutual Fund	21 L	459.56	1.87%	0.459%	-0
Multi Cap FundNEW	Nippon India Mutual Fund	19.01 L	416	0.74%	0.416%	—
Large and Midcap Fund	SBI Mutual Fund	15.29 L	334.54	0.79%	0.334%	-70,745
Large & Mid Cap Fund	DSP Mutual Fund	10.13 L	221.59	1.2%	0.221%	-0
Contra Fund	SBI Mutual Fund	9.95 L	217.75	0.46%	0.218%	-0

1–8 of 106

1 / 14

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Aug 2026TranscriptAI SummaryPPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

39 announcementsExport CSV

1 Oct 2026, 10:09 amCompany Update

Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc.

General PDF

28 Sept 2026, 3:42 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

28 Sept 2026, 9:11 amCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

21 Sept 2026, 4:14 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of ESOP / ESPS PDF

8 Sept 2026, 4:38 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

4 Sept 2026, 5:42 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

28 Aug 2026, 9:41 amCompany Update

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

General PDF

25 Aug 2026, 5:35 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of ESOP / ESPS PDF

Date	Category	Subject	Filing
1 Oct 2026, 10:09 am	Company Update General	Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc.	PDF
28 Sept 2026, 3:42 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.3%	64.7%	64.6%	60.5%	59.3%	66.8%	69.9%	73.8%
EBITDA margin %	15.5%	15.3%	16.9%	1.8%	10.8%	19%	23.3%	31.5%
EBIT margin %	8.8%	9%	11.1%	-8.4%	5.5%	13.1%	18.1%	26.6%
PAT margin %	3.8%	-1.8%	8.1%	-9.2%	2.7%	9.7%	14.6%	19.2%
Working capital
Receivable days	115	129	108	95	98	86	88	86
Inventory days	240	232	279	261	242	272	292	303
Payable days	156	162	137	129	136	163	158	208
NWC days	198	199	249	227	204	195	223	181
Leverage
Current ratio	2.26	1.67	1.66	1.51	1.34	1.58	1.87	1.9
Debt to EBITDA	—	—	1.86	13.38	2.36	0.7	0.96	0.67
Debt to equity	—	—	0.35	0.32	0.34	0.19	0.3	0.26
Interest coverage	7	5.1	12.9	-8.6	3.6	8.8	14.6	18.1
Asset turnover	0.59	0.62	0.64	0.75	0.72	0.83	0.78	0.73
Return ratios
Return on assets %	2.2%	-1.1%	5.2%	-6.9%	2%	8.1%	11.3%	14%
Return on capital employed %	10%	9.9%	11.7%	-8.6%	7.3%	18.7%	24.1%	34.2%
Return on equity %	4.5%	-2.2%	8.9%	-12.4%	3.6%	13.5%	19.2%	23.9%

Calls	Strike	Puts
0	0	0	₹0.0	1,680

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-369	4,114	209	3,111	1,469	1,239	1,082	1,934	3,490	430	7,546
	-6,943	-2,527	725	-2,865	1,107	-657	577	-1,324	-1,554	-1,602	-4,076
	5,813	433	-987	-295	-891	-1,885	-1,572	-337	-2,184	1,732	-846
Net cash flow	-1,500	2,019	-52	-50	1,685	-1,303	87	273	-248	560	2,624
Free cash flow	—	—	—	—	—	562	177	435	2,562	-1,252	5,491
CFO / Operating profit %	-10%	91.6%	7.2%	122.8%	62.4%	48.3%	376.9%	107.6%	91.6%	8.1%	85.6%

Lupin Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Segment results

Ratios

Shareholding

F&O

3

38

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

21

1

1

Announcements

Annual reports

Investor Presentation and earnings call

3

38

Segment results

Compounded sales growth

Compounded profit growth

Return on equity

Less: Inter segment Assets · revenue

Lupin Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Futures3

Option chain38

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Dividends21

Board meetings1

Stock splits1

Announcements

Annual reports

Investor Presentation and earnings call

Futures3

Option chain38

Profit & loss

Balance sheet

Segment results

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Less: Inter segment Assets · revenue

3

38

21

1

1

3

38